

## OUTSTANDING SUBB2M OVARIAN CANCER TEST DATA

- **Griffith University releases data on BARD1's SubB2M technology showing 100% specificity and sensitivity for detection of all stages of ovarian cancer**
- **Paper presenting this data at the Australia New Zealand Gynaecological Oncology Group (ANZGOG) Conference 2021**

**Melbourne, Australia, 11 February 2021:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that Griffith University's Institute of Glycomics has released data showing that SubB2M can be used to detect all stages of ovarian cancer with 100% specificity and 100% sensitivity.

SubB2M is a protein that binds specifically to a sugar molecule called Neu5Gc which is present on a range of cancers. In humans, Neu5Gc is only found on human tumour cells and tumour-associated molecules, potentially making Neu5Gc a highly specific pan-cancer biomarker. BARD1 holds the exclusive worldwide license for the use of SubB2M to detect any cancer.

Researchers from the University of Adelaide and Griffith University have engineered the SubB2M protein to have exquisite specificity for binding to Neu5Gc, and have proven its ability to detect Neu5Gc in the bloodstream of cancer patients.

The presentation entitled "*Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M*", was delivered by Dr Lucy Shewell from Griffith University's Institute for Glycomics at the ANZGOG Conference. Dr Shewell reported that serum from 47 patients with all stages of ovarian cancer had significantly elevated mean levels of Neu5Gc glycans compared to 22 cancer-free control individuals. She concluded that detection of Neu5Gc-glycans using SubB2M has the potential to be used as a diagnostic marker for the detection of early-stage ovarian cancer, as well as a tool for monitoring disease progression in late-stage cancer.

BARD1's CSO, Dr Peter French, said: "Whilst this data is preliminary, the outstanding results indicate the high specificity and sensitivity of SubB2M for ovarian cancer monitoring and detection. This work underpins BARD1's decision to license the technology and develop it for novel tests for breast, prostate and pancreatic cancers, as well as for ovarian cancer."

BARD1 CEO, Dr Leeorne Hinch, said: "The Company is focused on early detection of cancer and our SubB2M technology provides the potential for developing tests for monitoring and detection of multiple cancers. We will continue to collaborate with Griffith University to develop and validate commercial assays for monitoring treatment response and recurrence in ovarian cancer patients to improve health outcomes for this critical unmet medical need."

Griffith University's Professor Mike Jennings said: "The SubB2M technology has proved to have remarkable sensitivity and specificity for detection of these aberrant sugar blood biomarkers in the case of ovarian cancer and we look forward to working with BARD1 to get this test into clinical use".

Ovarian cancer is the leading cause of gynaecological cancer deaths worldwide, with around 295,000 new cases diagnosed and 185,000 deaths in 2018. Ovarian cancer is often diagnosed at a late stage, resulting in a poor prognosis with an overall 5-year survival rate of 46%.

*Authorised by the Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS

**Dr Leeorne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)  
M +61 417 203 021

### **ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

### **ABOUT GRIFFITH UNIVERSITY'S INSTITUTE FOR GLYCOMICS**

Griffith University's Institute for Glycomics is one of Australia's flagship multidisciplinary biomedical research institutes, comprising over 200 researchers, postgraduate students and support staff. The Institute for Glycomics strives to be a world leader in the discovery and development of novel drugs, vaccines and diagnostics through the application of innovative multidisciplinary science in a unique research environment. Their expertise centred around glycomics research makes them the only institute of its kind in Australia and one of only a handful in the world.

### **FORWARD LOOKING STATEMENTS**

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.